The Election Committee's proposal for approval by the Annual General Meeting of Active Biotech
Magnhild Sandberg-Wollheim, MD PhD, is a Professor of Neurology and Chief Medical Officer at the neurological clinic at Lund University Hospital. Dr. Sandberg has forty years experience treating patients with multiple sclerosis and her research has largely focused on clinical, immunological and genetic problems of this disease. Dr Sandberg is a member of the Swedish Neurological Society , the American Academy of Neurology, the Royal Physiographic Society and is an honorary member of the Swedish MS Association.
The Election Committee's complete proposals for decisions at the Annual General Meeting and additional information concerning the Board Member up for election, as well as an account of the work of the Election Committee, will be presented in conjunction with the publication of the notification of the Annual General Meeting.
Lund, March 15, 2007
Active Biotech AB (publ)
President and CEO
For further information, please contact:
Sven Andréasson, President and CEO, telephone: +46 (0)46-19 20 49
Cecilia Hofvander, Manager Corporate Communication, telephone: +46 (0)46-19 11 22
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.
Active Biotech AB (org.nr 556223-9227)
P.O. Box 724, SE-220 07 Lund, Sweden
Tel +46 46-19 20 00
Fax +46 46-19 20 50